These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22892449)

  • 21. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor eradication by hepatitis B virus X antigen-specific CD8+ T cells in xenografted nude mice.
    Chun E; Lee J; Cheong HS; Lee KY
    J Immunol; 2003 Feb; 170(3):1183-90. PubMed ID: 12538674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
    Tykodi SS; Fujii N; Vigneron N; Lu SM; Mito JK; Miranda MX; Chou J; Voong LN; Thompson JA; Sandmaier BM; Cresswell P; Van den Eynde B; Riddell SR; Warren EH
    Clin Cancer Res; 2008 Aug; 14(16):5260-9. PubMed ID: 18698046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.
    Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P
    Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
    Andersen R; Westergaard MCW; Kjeldsen JW; Müller A; Pedersen NW; Hadrup SR; Met Ö; Seliger B; Kromann-Andersen B; Hasselager T; Donia M; Svane IM
    Cancer Immunol Res; 2018 Feb; 6(2):222-235. PubMed ID: 29301752
    [No Abstract]   [Full Text] [Related]  

  • 27. A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors.
    Hung CF; Calizo R; Tsai YC; He L; Wu TC
    Vaccine; 2007 Jan; 25(1):127-35. PubMed ID: 16930783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a naturally processed HLA-A*02:01-restricted CTL epitope from the human tumor-associated antigen Nectin-4.
    Lopez M; Ghidouche A; Rochas C; Godelaine D; Carrasco J; Colau D; Hames G; Montero-Julian FA; Coulie PG; Olive D
    Cancer Immunol Immunother; 2016 Oct; 65(10):1177-88. PubMed ID: 27514672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.
    Barisic S; Brahmbhatt EM; Cherkasova E; Spear TT; Savani U; Pierre S; Scurti GM; Chen L; Igboko M; Nadal R; Zeng G; Parry G; Stroncek DF; Highfill S; Dalheim AV; Reger R; Nishimura MI; Childs RW
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39266213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.
    Meijer SL; Dols A; Urba WJ; Hu HM; Smith II JW; Vetto J; Wood W; Doran T; Chu Y; Sayaharuban P; Alvord WG; Fox BA
    J Immunother; 2002; 25(4):359-72. PubMed ID: 12142559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
    Dörrschuck A; Schmidt A; Schnürer E; Glückmann M; Albrecht C; Wölfel C; Lennerz V; Lifke A; Di Natale C; Ranieri E; Gesualdo L; Huber C; Karas M; Wölfel T; Herr W
    Blood; 2004 Oct; 104(8):2591-9. PubMed ID: 15231579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.
    Mami-Chouaib F; Echchakir H; Dorothée G; Vergnon I; Chouaib S
    Immunol Rev; 2002 Oct; 188():114-21. PubMed ID: 12445285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD8(+) T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway.
    Lionello I; Mangia P; Gattinoni L; Pende D; Cippone A; Sensi M; Rigatti P; Traversari C
    Cancer Immunol Immunother; 2007 Jul; 56(7):1065-76. PubMed ID: 17195078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
    Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
    J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy.
    Imahashi N; Nishida T; Ito Y; Kawada J; Nakazawa Y; Toji S; Suzuki S; Terakura S; Kato T; Murata M; Naoe T
    Mol Immunol; 2013 Dec; 56(4):399-405. PubMed ID: 23911395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
    Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
    J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.